Hypertensive exposure markers by MRI in relation to cerebral small vessel disease and cognitive impairment
Amier, R.P.; Marcks, N.; Hooghiemstra, A.M.; Nijveldt, R.; Buchem, M.A. van; Roos, A. de; ... ; Heart-Brain Connection Consortium

Citation

Version: Publisher's Version
License: [Leiden University Non-exclusive license](https://hdl.handle.net/1887/3214713)
Downloaded from: [https://hdl.handle.net/1887/3214713](https://hdl.handle.net/1887/3214713)

**Note:** To cite this publication please use the final published version (if applicable).
Hypertensive Exposure Markers by MRI in Relation to Cerebral Small Vessel Disease and Cognitive Impairment

Raquel P. Amier, MD,a Nick Marcks, MD,b Astrid M. Hooghiemstra, MD, PhD,c Robin Nijveldt, MD, PhD,a Mark A. van Buchem, MD, PhD,d Albert de Roos, MD, PhD,e L. Jaap Kappelle, MD, PhD,f Robert J. van Oostenbrugge, MD, PhD,f Rob J. van der Geest, MSc, PhD,g Michiel L. Bots, MSc, PhD,g Jacoba P. Greving, MSc, PhD,h Wiro J. Niessen, MSc, PhD,i Matthias J.P. van Osch, MD, PhD,j Jeroen de Bresser, MD, PhD,k Peter M. van de Ven, MSc, PhD,k Wiesje M. van der Flier, MSc, PhD,c,k Hans-Peter Brunner-La Rocca, MD, PhD,b Albert C. van Rossum, MD, PhD,a on behalf of the Heart-Brain Connection Consortium

ABSTRACT

OBJECTIVES This study sought to investigate the extent of hypertensive exposure as assessed by cardiovascular magnetic resonance imaging (MRI) in relation to cerebral small vessel disease (CSVD) and cognitive impairment, with the aim of understanding the role of hypertension in the early stages of deteriorating brain health.

BACKGROUND Preserving brain health into advanced age is one of the great challenges of modern medicine. Hypertension is thought to induce vascular brain injury through exposure of the cerebral microcirculation to increased pressure/pulsatility. Cardiovascular MRI provides markers of (subclinical) hypertensive exposure, such as aortic stiffness by pulse wave velocity (PWV), left ventricular (LV) mass index (LVMi), and concentricity by mass-to-volume ratio.

METHODS A total of 559 participants from the Heart-Brain Connection Study (431 patients with manifest cardiovascular disease and 128 control participants), age 67.8 ± 8.8 years, underwent 3.0-T heart-brain MRI and extensive neuropsychological testing. Aortic PWV, LVMi, and LV mass-to-volume ratio were evaluated in relation to presence of CSVD and cognitive impairment. Effect modification by patient group was investigated by interaction terms; results are reported pooled or stratified accordingly.

RESULTS Aortic PWV (odds ratio [OR]: 1.17; 95% confidence interval [CI]: 1.05 to 1.30 in patient groups only), LVMi (in carotid occlusive disease, OR: 5.69; 95% CI: 1.63 to 19.87; in other groups, OR: 1.30; 95% CI: 1.05 to 1.62) and LV mass-to-volume ratio (OR: 1.81; 95% CI: 1.46 to 2.24) were associated with CSVD. Aortic PWV (OR: 1.07; 95% CI: 1.02 to 1.13) and LV mass-to-volume ratio (OR: 1.27; 95% CI: 1.07 to 1.51) were also associated with cognitive impairment. Relations were independent of sociodemographic and cardiac index and mostly persisted after correction for systolic blood pressure or medical history of hypertension. Causal mediation analysis showed significant mediation by presence of CSVD in the relation between hypertensive exposure markers and cognitive impairment.

CONCLUSIONS The extent of hypertensive exposure is associated with CSVD and cognitive impairment beyond clinical blood pressure or medical history. The mediating role of CSVD suggests that hypertension may lead to cognitive impairment through the occurrence of CSVD. (J Am Coll Cardiol Img 2021;14:176-85) © 2021 Published by Elsevier on behalf of the American College of Cardiology Foundation.
Preserving brain health into advanced age has become one of the great challenges of modern medicine. Cardiovascular disease may contribute independently to cognitive impairment (1,2). As a consequence of increasing age in combination with better survival after acute cardiovascular events over the last decades (3), physicians are confronted with a shift to more chronic cardiovascular disease burden with potential detrimental, yet incompletely understood, effects on brain health.

Hypertension is a prominent determinant of chronic (subclinical) cerebral small vessel disease (CSVD), which, owing to advances in neuroimaging, is increasingly recognized as a cause of cognitive impairment (4–7). Exposure of the cerebral microcirculation to higher pressure and pulsatility induces a spectrum of cerebral microvascular remodeling and damage, including thickening of the arterial media, atherosclerotic plaque formation, endothelial dysfunction, increased blood-brain barrier permeability and microbleeds. These pathological microvascular changes may in turn also reduce cerebrovascular reactivity, thus affecting the capability of the brain to maintain adequate blood flow in low pressure or low flow settings and rendering the brain vulnerable to (subclinical) ischemic injury as well (1,8–10).

With a focus on detecting and understanding the early subclinical stages of deteriorating brain health, investigating hypertensive exposure may provide more in-depth insight into the role of hypertensive disease in the pathophysiology of cognitive impairment. However, quantifying hypertensive exposure based on clinical characteristics is hampered by difficulties in assessing or defining factors such as duration, initial severity of hypertension, adequate patient compliance, some of which may also vary over time. Alternatively, cardiovascular magnetic resonance imaging (MRI) allows assessment of cardiovascular remodeling in response to hypertension. Hypertensive exposure markers include left ventricular (LV) mass index (LVMi), LV mass-to-volume ratio indicating concentricity, and aortic pulse wave velocity (PWV) indicating arterial stiffness.

The current study investigated the relation of hypertensive exposure markers by cardiovascular MRI with the presence of CSVD assessed by brain MRI and lower cognitive functioning in a population of patients with manifest cardiovascular disease and control participants.

**METHODS**

**STUDY POPULATION.** For the current study, baseline data of Heart-Brain Connection Study participants were used. The Heart-Brain Connection Study is a multicenter, prospective, observational study investigating the interplay of cardiovascular and hemodynamic factors in the pathophysiology of cognitive impairment; rationale and methods were described previously (11).

The study population consisted of patients with a clinical diagnosis of heart failure (HF) (n = 162), vascular cognitive impairment (VCI) (n = 160), or carotid occlusive disease (COD) (n = 109) and a group of control participants (n = 128), enrolled between September 2014 and December 2017 in 4 university medical centers in the Netherlands. HF was defined following European Society of Cardiology Guidelines (12), and patients were clinically stable for at least 6 months before enrollment. VCI was defined as cognitive complaints in the absence of dementia (Clinical Dementia Rating: ≤1 and Mini-Mental State Examination: ≤20), with at least moderate vascular brain injury on brain MRI or mild vascular brain injury in the presence of vascular risk factors or a history of manifest vascular disease. COD was defined as significant stenosis >80% or occlusion of an internal carotid artery not scheduled for surgical intervention. Patients were enrolled from cardiology, memory, and neurology outpatient clinics. Control participants were recruited via advertising leaflets and by

Abbreviations and Acronyms

- **BP** = blood pressure
- **CI** = confidence interval
- **COD** = carotid occlusive disease
- **CSVD** = cerebral small vessel disease
- **HF** = heart failure
- **LV** = left ventricle
- **LVMi** = left ventricular mass index
- **MRI** = magnetic resonance imaging
- **OR** = odds ratio
- **PWV** = pulse wave velocity
- **VCI** = vascular cognitive impairment

*Department of Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; Biomedical Imaging Group Rotterdam and Departments of Medical Informatics and Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands; Department of Imaging Physics, Applied Sciences, Delft University of Technology, Delft, the Netherlands; C.J. Gorter Center for High-Field Magnetic Resonance Imaging, Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; and the Department of Epidemiology and Biostatistics, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.

Manuscript received February 14, 2020; revised manuscript received June 15, 2020, accepted June 30, 2020.
approaching spouses of participants when they fulfilled the selection criteria. Inclusion criteria for all participants were age ≥50 years, ability to undergo cognitive testing, and independence in daily life. We excluded those with a contraindication for MRI, life-threatening disease with life expectancy of <3 years, neurodegenerative disease other than VCI or Alzheimer disease, neurologic or psychiatric diagnosis that could affect cognitive performance, and, for technical reasons, atrial fibrillation upon enrollment (of note, previous or paroxysmal atrial fibrillation was not an exclusion criterion) and premature ventricular contractions of >10% of heartbeats. For control participants, the only additional exclusion criterion was a prior diagnosis of HF, VCI, or COD; that is, controls were not excluded in the case of other manifestations of cardiovascular disease or risk factors.

All participants provided written informed consent. This study was performed in accordance with the Declaration of Helsinki and with approval from the Medical Ethics Review Committee of Leiden University Medical Center and the locally appointed ethics committees of all other participating centers.

CLINICAL CHARACTERISTICS. Sociodemographic characteristics and medical history of cardiovascular and cerebrovascular disease and risk factors were obtained via questionnaires. Anthropometrics included height, weight, waist and hip circumference, and brachial office blood pressure (BP) measurement with a digital sphygmomanometer in the sitting position after 5 min of resting. A waist-hip ratio of ≥0.90 for men and ≥0.85 for women was considered obese, according to the World Health Organization cutoff values (13).

HEART-BRAIN MRI PROTOCOL. Heart-brain MRI was performed on 3.0-T clinical MR scanners (Ingenia or Achieva, Philips, Best, the Netherlands). The cardiovascular MRI protocol consisted of breath-hold electrocardiography-gated, steady-state, free precession cine imaging performed in standard long- and short-axis orientations covering the whole LV. Typical parameters were as follows: spatial resolution: 1.5 × 1.6 × 8.0 mm; repetition time: 3.1 ms; echo time: 1.55; flip angle: 45°; 40 heart phases; and 67% phase percentage. Additionally, for assessment of aortic PWV, through-plane velocity-encoded phase contrast imaging was performed through the ascending and descending aorta at the level of the pulmonary artery. Typical parameters were as follows: spatial resolution: 2.5 × 2.5 × 8.0 mm; TR: 4.7 ms; TE: 2.8 ms; flip angle: 10°; velocity encoding: 150 cm/s; maximal number of heart phases dependent on heart rate (typically approximately 150 to 180 heart phases); temporal resolution: 5 ms.

For the brain MRI protocol, T1-weighted imaging was performed with the following typical parameters: 3-dimensional T1; spatial resolution: 1.0 × 1.0 × 1.0 mm; TR: 8.2 ms; TE: 4.5 ms. Furthermore, fluid attenuation inversion recovery images (spatial resolution: 1.11 × 1.11 × 1.11 mm; TR: 4,800 ms; TE: 313 ms; TI: 1,650 ms) and susceptibility-weighted imaging (spatial resolution: 0.8 × 0.8 × 1.6 mm; TR: 45 ms; TE: 31 ms) were performed.

IMAGE ANALYSIS. Cardiovascular. On short-axis cine images, LV end-diastolic endocardial and epicardial contours and end-systolic endocardial contours were defined by semiautomatic contours with manual correction to calculate LV end-diastolic and end-systolic volumes, LV ejection fraction, and LV (end-diastolic) mass. Papillary muscles were excluded from endocardial contours and included in the LV blood pool. LV end-diastolic myocardial volume was multiplied by 1.05 to calculate LV mass. To correct for the effect of body size, LV mass was divided by body surface area (DuBois & DuBois formula) to calculate LVMi. LV concentricity was assessed by LV mass-to-volume ratio, defined as LV mass divided by LV end-diastolic volume. Aortic PWV, reflecting aortic stiffness, was calculated as distance/transit time, where distance was defined as length of the aortic arch between imaging planes through the ascending and descending aorta, and transit time was defined as the time between pulse waves at the ascending and descending aorta by the foot-to-foot method. All analyses were performed on Mass version August 2017 (Medis medical imaging systems, Leiden, the Netherlands). LV and PWV analyses were performed separately, both by an experienced reader who was blinded to all other patient data.

Brain. Brain MRI markers of CSVD (white matter hyperintensities and lacunes of presumed vascular origin, microbleeds, and moderately to severely enlarged perivascular spaces in the basal ganglia) were visually scored on T1-weighted fluid attenuation inversion recovery images. White matter hyperintensities were graded using the Fazekas scale (0 to 3). The Staals classification was used to determine presence of CSVD (defined as a Staals classification of >1, which consists of 1 or more of the following findings: white matter hyperintensities with Fazekas score >1; ≥1 microbleed; ≥1 lacunar infarct; and moderately to severely enlarged perivascular spaces in the basal ganglia) (14). To minimize variation in the
Cognitive impairment was determined using standardized neuropsychological tests (14, 15). All participants underwent an extensive and standardized cognitive test battery based on the Dutch Parelsnoer Initiative (16), providing cognitive functioning in the following four major cognitive domains: memory, language, attention-psychomotor speed, and executive functioning. Cognitive test scores were transformed to $z$-scores with control participants as the reference and were corrected for age, sex, and years of education. Cognitive impairment was defined as $z$-score lower than $-1.5$ in $\geq 1$ cognitive domain.

### STATISTICAL METHODS

Continuous variables are presented as mean $\pm$ SD or median (interquartile range). Logistic regression analyses were performed to investigate the relations of hypertensive exposure markers with presence of CSVD and with cognitive impairment. All analyses concerning CSVD were adjusted for age, sex, and education. All analyses concerning cognitive impairment were adjusted for cardiac index (as note, cognitive test scores were calculated with correction for age, sex, and education). Odds ratios (ORs) for aortic PWV are reported per 1-m/s increment; for LVMI, per 10-g/m$^2$ increment; and for LV mass-to-volume ratio, per 0.10-g/ml increment. Two-sided p values of $<0.05$ were considered statistically significant. Analyses were performed using IBM SPSS Statistics, version 22 (IBM, Armonk, New York).

### Table 1: Characteristics of the Study Participants

<table>
<thead>
<tr>
<th></th>
<th>All Participants (N = 559)</th>
<th>HF (n = 162)</th>
<th>VCI (n = 160)</th>
<th>COD (n = 109)</th>
<th>Control Participants (n = 128)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yrs</td>
<td>67.8 $\pm$ 8.8</td>
<td>69.7 $\pm$ 10.0</td>
<td>68.8 $\pm$ 8.4</td>
<td>66.4 $\pm$ 8.0</td>
<td>65.6 $\pm$ 7.4</td>
</tr>
<tr>
<td>Female</td>
<td>200 (35.8)</td>
<td>54 (33.3)</td>
<td>61 (38.1)</td>
<td>25 (22.9)</td>
<td>60 (46.9)</td>
</tr>
<tr>
<td>Education, yrs</td>
<td>13.4 $\pm$ 4.4</td>
<td>13.2 $\pm$ 4.7</td>
<td>13.8 $\pm$ 4.2</td>
<td>12.3 $\pm$ 3.8</td>
<td>14.2 $\pm$ 4.4</td>
</tr>
<tr>
<td>Mini Mental State Exam score</td>
<td>29 (27-30)</td>
<td>29 (28-30)</td>
<td>28 (26-29)</td>
<td>28 (27-29)</td>
<td>29 (28-30)</td>
</tr>
<tr>
<td>Current smoking</td>
<td>91 (16.3)</td>
<td>24 (14.9)</td>
<td>29 (18.1)</td>
<td>30 (27.8)</td>
<td>8 (6.3)</td>
</tr>
<tr>
<td>Former smoking</td>
<td>318 (57.1)</td>
<td>91 (56.5)</td>
<td>92 (57.5)</td>
<td>72 (66.7)</td>
<td>63 (49.2)</td>
</tr>
<tr>
<td>Body mass index &gt;25 kg/m$^2$</td>
<td>361 (65.0)</td>
<td>111 (69.4)</td>
<td>94 (59.1)</td>
<td>79 (73.2)</td>
<td>77 (44.5)</td>
</tr>
<tr>
<td>Waist-to-hip ratio, obese</td>
<td>430 (78.9)</td>
<td>129 (83.8)</td>
<td>121 (77.6)</td>
<td>97 (89.8)</td>
<td>83 (65.4)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>315 (56.8)</td>
<td>86 (53.8)</td>
<td>115 (71.9)</td>
<td>81 (75.7)</td>
<td>33 (25.8)</td>
</tr>
<tr>
<td>Untreated hypertension</td>
<td>28 (8.9)</td>
<td>5 (5.8)</td>
<td>11 (9.6)</td>
<td>8 (9.9)</td>
<td>4 (12.1)</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>311 (56.3)</td>
<td>75 (47.2)</td>
<td>106 (67.1)</td>
<td>92 (86.0)</td>
<td>38 (29.7)</td>
</tr>
<tr>
<td>Untreated hypercholesterolemia</td>
<td>37 (11.9)</td>
<td>8 (10.7)</td>
<td>15 (14.3)</td>
<td>4 (4.3)</td>
<td>10 (26.3)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>82 (14.7)</td>
<td>29 (18.0)</td>
<td>19 (11.8)</td>
<td>31 (28.9)</td>
<td>3 (2.3)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>120 (21.6)</td>
<td>82 (50.9)</td>
<td>18 (11.3)</td>
<td>16 (15.0)</td>
<td>4 (3.1)</td>
</tr>
<tr>
<td>Percutaneous coronary intervention</td>
<td>107 (19.2)</td>
<td>62 (38.5)</td>
<td>17 (10.6)</td>
<td>22 (20.6)</td>
<td>6 (4.7)</td>
</tr>
<tr>
<td>Coronary artery bypass grafting</td>
<td>57 (10.3)</td>
<td>31 (19.3)</td>
<td>6 (3.8)</td>
<td>16 (15.0)</td>
<td>4 (3.1)</td>
</tr>
<tr>
<td>Transient ischemic attack</td>
<td>140 (25.2)</td>
<td>16 (9.9)</td>
<td>38 (23.9)</td>
<td>79 (73.8)</td>
<td>7 (5.5)</td>
</tr>
<tr>
<td>Cerebrovascular attack</td>
<td>130 (23.2)</td>
<td>9 (5.6)</td>
<td>66 (41.3)</td>
<td>55 (50.5)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Office systolic BP, mm Hg</td>
<td>142 $\pm$ 21</td>
<td>135 $\pm$ 19</td>
<td>142 $\pm$ 22</td>
<td>152 $\pm$ 22</td>
<td>143 $\pm$ 19</td>
</tr>
<tr>
<td>Office diastolic BP, mm Hg</td>
<td>80 $\pm$ 11</td>
<td>77 $\pm$ 11</td>
<td>81 $\pm$ 11</td>
<td>82 $\pm$ 12</td>
<td>82 $\pm$ 10</td>
</tr>
<tr>
<td>Office heart rate, beats/min</td>
<td>67 $\pm$ 11</td>
<td>65 $\pm$ 11</td>
<td>68 $\pm$ 11</td>
<td>69 $\pm$ 11</td>
<td>66 $\pm$ 11</td>
</tr>
<tr>
<td>Office BP $&gt;$140/90 mm Hg</td>
<td>305 (55.3)</td>
<td>68 (42.8)</td>
<td>88 (55.3)</td>
<td>78 (73.6)</td>
<td>71 (55.5)</td>
</tr>
<tr>
<td>Office BP $&gt;$130/80 mm Hg</td>
<td>440 (79.7)</td>
<td>110 (69.2)</td>
<td>127 (79.9)</td>
<td>97 (91.5)</td>
<td>106 (82.8)</td>
</tr>
<tr>
<td>LV end-diastolic volume, ml</td>
<td>161 (134-199)</td>
<td>206 (162-243)</td>
<td>147 (121-173)</td>
<td>160 (143-175)</td>
<td>151 (129-177)</td>
</tr>
<tr>
<td>LV end-systolic volume, ml</td>
<td>71 (53-100)</td>
<td>116 (85-154)</td>
<td>60 (48-79)</td>
<td>66 (52-79)</td>
<td>61 (49-74)</td>
</tr>
<tr>
<td>LV ejection fraction, %</td>
<td>55 (46-61)</td>
<td>43 (36-49)</td>
<td>58 (53-63)</td>
<td>58 (54-64)</td>
<td>59 (55-63)</td>
</tr>
<tr>
<td>LV mass, g</td>
<td>97 (79-117)</td>
<td>110 (88-128)</td>
<td>93 (74-109)</td>
<td>108 (91-123)</td>
<td>84 (71-103)</td>
</tr>
<tr>
<td>LV mass index, g/m$^2$</td>
<td>50 (43-58)</td>
<td>56 (47-64)</td>
<td>49 (41-54)</td>
<td>53 (46-62)</td>
<td>44 (39-50)</td>
</tr>
<tr>
<td>LV mass-to-volume ratio, g/ml</td>
<td>0.60 $\pm$ 0.12</td>
<td>0.55 $\pm$ 0.11</td>
<td>0.62 $\pm$ 0.10</td>
<td>0.69 $\pm$ 0.11</td>
<td>0.57 $\pm$ 0.09</td>
</tr>
<tr>
<td>Aortic pulse wave velocity, m/s</td>
<td>8.4 (6.8-10.8)</td>
<td>7.9 (6.2-10.2)</td>
<td>9.0 (7.3-11.1)</td>
<td>9.0 (7.5-12.1)</td>
<td>8.2 (6.3-10.4)</td>
</tr>
</tbody>
</table>

Values are mean $\pm$ SD, n (%), or median (interquartile range). BP = blood pressure; COD = carotid occlusive disease; HF = heart failure; LV = left ventricular; VCI = vascular cognitive impairment.
Effect modification by patient group (HF, VCI, COD, or control) was assessed by interaction terms for each analysis. Results are reported stratified in the case of significant effect modification ($p < 0.10$); otherwise, results are reported based on pooled data.

Causal mediation analysis was performed in R, version 3.5.3 (R Foundation for Statistical Computing, Vienna, Austria) using Mediation Package, version 4.4.7 to assess whether the presence of CSVD mediates the relation between hypertensive exposure markers and cognitive impairment. Logistic regression models were used to regress the mediator (presence of CSVD; dichotomous) on $X$ (hypertensive exposure markers; continuous) and to regress $Y$ (cognitive impairment; dichotomous) on mediator

The arrows indicate examples of white matter hyperintensities, microbleeds, lacunar infarct, and perivascular spaces as shown by brain MRI.

FLAIR = fluid attenuation inversion recovery; MRI = magnetic resonance imaging; SWI = susceptibility-weighted imaging; T1W = T1 weighted.
and X. Mediation analyses were repeated, allowing for an interaction between X and the mediator.

**RESULTS**

Participants were, on average, 67.8 ± 8.8 years of age, and 35.8% of participants were female. Table 1 shows detailed characteristics for the total study population and per patient group.

Cardiovascular MRI data were available in 529 (94.6%) participants and brain MRI data in 558 (99.8%) participants. Examples of CSVD by brain MRI are shown in Figure 1. CSVD was detected in 68.7% of participants and cognitive impairment in $1 domain in 26.9% of participants (Table 2, Central Illustration).

**HYPERTENSIVE EXPOSURE MARKERS IN RELATION TO BRAIN OUTCOME.** Aortic PWV was associated with CSVD (OR: 1.17; 95% confidence interval [CI]: 1.05 to 1.30; $p = 0.003$) in patients with HF, VCI, and COD but not in control participants (Table 3). LVMi was associated with CSVD in all patient groups, although the relation was more prominent in patients with COD (OR: 5.69; 95% CI: 1.63 to 19.87; $p = 0.006$) compared to patients with HF, patients with VCI, and control participants (OR: 1.30; 95% CI: 1.05 to 1.62; $p = 0.017$). LV mass-to-volume ratio was significantly associated with CSVD in all participants (OR: 1.81; 95% CI: 1.46 to 2.24; $p < 0.001$).

Aortic PWV (OR: 1.07; 95% CI: 1.02 to 1.13; $p = 0.009$) and LV mass-to-volume ratio (OR: 1.27; 95% CI: 1.07 to 1.51; $p = 0.007$) were associated with cognitive impairment in $1 domain among all participants, whereas LVMi was not.

Relations of hypertensive exposure markers with CSVD and cognitive impairment showed no important change after additional correction for systolic BP. Correction for medical history of hypertension did not affect the relation of LVMi with CSVD in patients with COD (OR: 5.77; 95% CI: 1.63 to 20.39; $p = 0.007$) but attenuated the association of LVMi with CSVD in patients with HF, patients with VCI, and control participants (OR: 1.22; 95% CI: 0.99 to 1.50; $p = 0.062$). Relations of aortic PWV and LV mass-to-volume ratio with CSVD and with cognitive impairment were not affected by correction for medical history of hypertension.

**MEDIATION BY CSVD.** Causal mediation analysis showed significant mediation by presence of CSVD for all 3 hypertensive exposure markers in relation to cognitive impairment (Central Illustration and Supplemental Table 1). In the relation between aortic PWV and cognitive impairment, 44.6% of the total effect was attributable to mediation by the presence of CSVD ($p = 0.004$). The mediation effect was 89.5% ($p = 0.022$) for LVMi and 59.0% ($p < 0.001$) for LV mass-to-volume ratio in their respective relations with cognitive impairment. Conclusions did not change when the possible interaction between hypertensive exposure markers and CSVD was taken into account.

**DISCUSSION**

The main findings of this study are that hypertensive exposure markers by cardiovascular MRI are associated with presence of CSVD by brain MRI and with...
The distribution of cerebral small vessel disease and cognitive impairment are shown for each hypertensive exposure marker. Causal mediation analysis is shown for cerebral small vessel disease as a mediator in the relation between hypertensive exposure markers and cognitive impairment. (Effects are risk differences resulting from change in hypertensive exposure marker from the 25th to 75th percentile). The mediation effect is the indirect effect expressed as a percentage of the total effect, that is, the proportion of the relation between the independent and dependent variables attributable to mediation. LV = left ventricular.
cognitive impairment in ≥1 domain and that the presence of CSVD is a significant mediator in the relation between hypertensive exposure and cognitive impairment. Aortic PWV, LVMi, and LV mass-to-volume ratio were all associated with CSVD—aortic PWV only in patients with cardiovascular disease and LVMi and LV mass-to-volume ratio in all participants. Both aortic PWV and LV mass-to-volume ratio were also associated with cognitive impairment in all participants. The relations of hypertensive exposure markers with poorer brain health largely persisted after correction for either systolic BP or medical history of hypertension. These findings indicate that the impact of hypertension on brain structure and function is not an on/off phenomenon but, rather, a sliding scale, where an increasing extent of hypertensive exposure (i.e., severity and/or duration of hypertension) is related to higher rates of CSVD and cognitive impairment. Moreover, although no temporal relations can be assumed from this cross-sectional study, causal mediation analysis supports the hypothesis that hypertensive exposure may lead to CSVD, which, in turn, may lead to cognitive impairment.

Compared to previous studies, important strengths of our study are the assessment of multiple hypertensive exposure markers; use of optimal imaging modalities for both cardiovascular remodeling and vascular brain injury assessment; high-resolution brain MRI, allowing more sensitive detection of CSVD; and comprehensive assessment of cognitive functioning. Our results are largely in line with those of previous studies. LVMi by echo-cardiography or cardiovascular MRI has been linked to declining white matter microstructural integrity, white matter hyperintensities, poorer cognitive functioning, and incident dementia (17–21). LV mass-to-volume ratio was included in a previous study and was related to poorer cognitive functioning and incident dementia in a geriatric population (20). To our knowledge, no other data are yet available on LV-mass-to-volume ratio in relation to vascular brain injury. Aortic PWV by cardiovascular MRI has been linked to white matter hyperintensities and, in patients with hypertension, to lacunar infarcts as well (22–24). Vascular applanation tonometry-based measures of global PWV (carotid-femoral or brachial-ankle) have repeatedly been linked to white matter hyperintensities and lower cognitive performance in the general population, elderly individuals, and patients with hypertension (25–30). Carotid-femoral PWV also indicated higher a risk of conversion to dementia in elderly patients with mild cognitive impairment, during a mean follow-up of 4.5 years (31).

Although LVMi and LV mass-to-volume ratio are both thought to reflect cardiac remodeling in response to hypertension, LVMi was not related to cognitive impairment, and the relation with CSVD was less robust (i.e., independent of medical history of hypertension only in patients with COD). One previous study in elderly cardiac outpatients found no significant relation of LVMi with cognitive performance, and other studies have reported conflicting results on whether this relation was independent of BP (19–21,32). LVMi is a structural parameter, whereas LV mass-to-volume ratio is a geometric parameter indicating an increase in LV mass relative to LV dimensions. Because the total amount of myocardium will also increase with general cardiac enlargement for reasons unrelated to hypertensive exposure, LVMi may become less specific for hypertensive exposure in populations with higher rates of manifest cardiovascular disease. LV mass-to-volume ratio can, however, indicate relative hypertrophy even in dilated LVs and may therefore be more suited for application in a clinical setting.
Increasing evidence is showing that the impact of hypertension on the brain is broader than previously recognized and involves subclinical repetitive microinjuries that may contribute to cognitive impairment over time (33,34). Whether specific patient populations with higher cardiovascular disease burden could benefit from more intensive BP management (e.g., <120 mm Hg target systolic BP) is yet to be determined, although the ACCORD (Action to Control Cardiovascular Risk in Diabetes), SPRINT (Systolic Blood Pressure Intervention Trial), and INFINITY (Intensive Versus Standard Ambulatory Blood Pressure Lowering to Prevent Functional Decline In the Elderly) trials have shown promising effects on reducing the progression of vascular brain injury, with varying effects on cognitive functioning (35–39). The results of our study also suggest that chronicity of inadequate BP control may be an important factor in the relation between hypertension and poorer brain health.

Clinical awareness of the vascular vulnerability of the brain may be warranted, especially in elderly patients and those with high cardiovascular disease burden. When cerebral homeostatic mechanisms are compromised, regulating BP may become a delicate balance of reducing potential harm by increased pressure/pulsatility while preventing episodes of low-grade ischemia. This increasing complexity within individual patients will likely require multidisciplinary approaches for optimal evaluation and management, in which cardiovascular imaging markers may contribute to more accurate detection of those most vulnerable to vascular brain injury and cognitive impairment attributable to hypertension.

STUDY LIMITATIONS. The cross-sectional nature of our study allows the investigation of only associations. The Heart-Brain Connection Study included several patient populations with specific manifestations of cardiovascular disease and was not specifically designed to investigate hypertension. Therefore, possible effect modification by patient group was checked for in each analysis to ensure that associations were similar across all groups before pooling data and to ensure that associations were not driven by 1 specific patient group. Finally, although none of our participants had a medical history of hypertrophic cardiomyopathy, aortic valve stenosis, sarcoidosis, or amyloidosis, it should be noted that considering LVMi and LV mass-to-volume ratio as markers of hypertensive exposure is only appropriate in absence of a primary cardiac cause of hypertrophy.

CONCLUSIONS

The extent of hypertensive exposure assessed by cardiovascular MRI is associated with higher rates of CSVD and cognitive impairment in patients with cardiovascular disease and control individuals. A substantial proportion of the relation between hypertensive exposure markers and cognitive impairment may be attributable to the presence of CSVD, as suggested by causal mediation analysis. These findings also suggest that cardiovascular imaging markers of hypertensive exposure may be useful to detect those most vulnerable to vascular brain injury and cognitive impairment related to hypertension.

AUTHOR DISCLOSURES

The Heart-Brain Connection Study group was supported by the Netherlands Cardiovascular Research Initiative: the Dutch Heart Foundation (CVON 2012-06 Heart-Brain Connection), Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences. None of the authors have direct or indirect relationships with the Netherlands CardioVascular Research Initiative. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr. Albert C. van Rossum, Department of Cardiology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands. E-mail: ac.vrossum@amsterdamumc.nl.

PERSPECTIVES

COMPETENCY IN MEDICAL KNOWLEDGE: Hypertensive disease involves subclinical, repetitive cerebrovascular microinjuries that may cause cognitive impairment over time.

COMPETENCY IN PATIENT CARE: Clinical awareness of vascular vulnerability of the brain is warranted, especially in elderly patients and in those with high cardiovascular disease burden.

TRANSLATIONAL OUTLOOK 1: When cerebral homeostatic mechanisms are compromised by the presence of cerebral small vessel disease, regulating blood pressure may become a delicate balance of reducing further harm by high blood pressure while preventing episodes of low-grade ischemia.

TRANSLATIONAL OUTLOOK 2: Longitudinal cohort studies should investigate the temporal relations of vascular brain injury and cognitive impairment to further investigate the complex causal mechanisms.